Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes
Author(s) -
Francesca Santilli,
Paola Simeone,
Maria Teresa Guagnano,
Marika Leo,
Marica Tina Maccarone,
Augusto Di Castelnuovo,
Cristina Sborgia,
Riccardo C. Bonadonna,
E Angelucci,
Virginia Federico,
Stefano Cianfarani,
Lamberto Manzoli,
Giovanni Davı̀,
Armando Tartaro,
Agostino Consoli
Publication year - 2017
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc17-0589
Subject(s) - medicine , liraglutide , prediabetes , type 2 diabetes , weight loss , diabetes mellitus , endocrinology , obesity
Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associated with weight loss, improved glycemic control, and reduced cardiovascular risk. We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom